Literature DB >> 10390778

[Symptomatic sinus bradycardia associated with donepezil].

J M Calvo-Romero1, J L Ramos-Salado.   

Abstract

INTRODUCTION: Donepezil is a drug which is being used more and more widely in mild-moderate Alzheimer's disease. In general, it is well tolerated and the side-effects are basically cholinergic-dependent. Symptomatic disorders of cardiac rhythm associated with the use of donepezil are extremely unusual. CLINICAL CASE: We describe the case of an 81 year old patient with hypertensive cardiopathy, who developed sinus bradycardia, fainting and left cardiac failure three weeks after starting treatment with donepezil. When donepezil was stopped the sinus bradycardia disappeared, a 24 hour electrocardiographic holter showed no signs of sinus node disease and no episodes of this type occurred during the following six months.
CONCLUSION: Symptomatic sinus bradycardia is a possible adverse effect of treatment with donepezil in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10390778

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

1.  Donepezil-associated bradyarrhythmia in a patient with dementia with Lewy bodies (DLB).

Authors:  Michael H Rosenbloom; Richard Finley; Melvin M Scheinman; Mitchell D Feldman; Bruce L Miller; Gil D Rabinovici
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

Review 2.  Collapse in the elderly: rivastigmine-induced heart block and a literature review of the pharmacology of acetylcholinesterase inhibitors used in Alzheimer's disease.

Authors:  Olushola Alonge; Fahad Mujtaba Iqbal; Elzbieta Cifonelli
Journal:  BMJ Case Rep       Date:  2018-04-17

3.  Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil.

Authors:  T Suleyman; P Tevfik; G Abdulkadir; S Ozlem
Journal:  Emerg Med J       Date:  2006-08       Impact factor: 2.740

4.  Cardiovascular effects and risk of syncope related to donepezil in patients with Alzheimer's disease.

Authors:  Philippe Bordier; Stephane Garrigue; Stephane Lanusse; Julien Margaine; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

5.  Causes of syncope in patients with Alzheimer's disease treated with donepezil.

Authors:  Philippe Bordier; Stephane Lanusse; Stephane Garrigue; Charlotte Reynard; Frederic Robert; Laurent Gencel; Alexia Lafitte
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada.

Authors:  Allen R Huang; Calum J Redpath; Carl van Walraven
Journal:  BMC Neurol       Date:  2015-04-28       Impact factor: 2.474

7.  Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; Ping Li; Sudeep S Gill; Andreas Laupacis; David N Juurlink
Journal:  PLoS Med       Date:  2009-09-29       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.